F Qian1, Y Qingping2, W Linquan1, H Xiaojin2, W Rongshou3, R Shanshan4, L Wenjun1, H Yong5, L Enliang6. 1. Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China. 2. Department of Assisted Reproductive, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China. 3. Department of General Surgery, The First Affiliated Hospital of Gannan Medical, Ganzhou 341000, China. 4. Department of Operating Room, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China. 5. Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China. Electronic address: huangyong2004373@163.com. 6. Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China. Electronic address: lienliangyx@163.com.
Abstract
AIMS: Tumor-infiltrating FoxP3+ T cells and FoxP3+ tumor cells have been reported in breast cancer (BC), which impaired immunity and promoted tumors progression. However, their prognostic value for survival in patients with breast BC remains controversial. METHODS: A meta-analysis was performed. Original data included the hazard ratios (HR) of overall survival (OS), relapse-free survival and odds ratio (OR) in BC patients. We pooled HR/OR with 95% confidence intervals (CI) to estimate the hazard. RESULTS: The overall survival of high tumor-infiltrating FoxP3+ T cells patients was lower than low tumor-infiltrating FoxP3+ T cells patients with estrogen receptor (ER)-positive (HR 0.86, 95% CI 0.77-0.96; P = 0.009) but not ER-negative (HR 1.09, 95% CI 0.82-1.45; P = 0.569) BC. And FoxP3+ tumor cells were not associated with the overall survival and recurrences of BC patients (P > 0.05). In addition, a significant association was revealed between high tumor-infiltrating FoxP3+ T cells and grade (I + II/III: OR 0.31, 95% CI 0.17-0.56; P < 0.001), ER status (present: OR 2.39, 95% CI 1.51-3.76; P < 0.001), HER2 status (present: OR 0.53, 95% CI 0.36-0.78; P = 0.001), PR status (present: OR 1.88, 95% CI 1.31-2.71; P < 0.001). And a significant association was revealed between positive FoxP3+ tumor cells and Nodal status (present: OR 0.48, 95% CI 0.23-0.97; P = 0.04), grade (I + II/III: OR 0.44, 95% CI 0.22-0.85; P = 0.01), PR status (present: OR 2.37, 95% CI 1.54-3.36; P < 0.001). CONCLUSIONS: High tumor-infiltrating FoxP3+ T cells were associated with a poorer prognosis for ER-positive BC, but not for ER-negative BC.
AIMS: Tumor-infiltrating FoxP3+ T cells and FoxP3+ tumor cells have been reported in breast cancer (BC), which impaired immunity and promoted tumors progression. However, their prognostic value for survival in patients with breast BC remains controversial. METHODS: A meta-analysis was performed. Original data included the hazard ratios (HR) of overall survival (OS), relapse-free survival and odds ratio (OR) in BC patients. We pooled HR/OR with 95% confidence intervals (CI) to estimate the hazard. RESULTS: The overall survival of high tumor-infiltrating FoxP3+ T cells patients was lower than low tumor-infiltrating FoxP3+ T cells patients with estrogen receptor (ER)-positive (HR 0.86, 95% CI 0.77-0.96; P = 0.009) but not ER-negative (HR 1.09, 95% CI 0.82-1.45; P = 0.569) BC. And FoxP3+ tumor cells were not associated with the overall survival and recurrences of BC patients (P > 0.05). In addition, a significant association was revealed between high tumor-infiltrating FoxP3+ T cells and grade (I + II/III: OR 0.31, 95% CI 0.17-0.56; P < 0.001), ER status (present: OR 2.39, 95% CI 1.51-3.76; P < 0.001), HER2 status (present: OR 0.53, 95% CI 0.36-0.78; P = 0.001), PR status (present: OR 1.88, 95% CI 1.31-2.71; P < 0.001). And a significant association was revealed between positive FoxP3+ tumor cells and Nodal status (present: OR 0.48, 95% CI 0.23-0.97; P = 0.04), grade (I + II/III: OR 0.44, 95% CI 0.22-0.85; P = 0.01), PR status (present: OR 2.37, 95% CI 1.54-3.36; P < 0.001). CONCLUSIONS: High tumor-infiltrating FoxP3+ T cells were associated with a poorer prognosis for ER-positive BC, but not for ER-negative BC.
Authors: Alexandra Giatromanolaki; Anastasia G Gkegka; Stamatia Pouliliou; Eirini Biziota; Stylianos Kakolyris; Michael Koukourakis Journal: Breast Cancer Res Treat Date: 2022-04-28 Impact factor: 4.872
Authors: Rashmi Verma; Andrew M Hanby; Kieran Horgan; Eldo T Verghese; Milene Volpato; Clive R Carter; Thomas A Hughes Journal: Breast Cancer Res Treat Date: 2020-06-23 Impact factor: 4.872